An overview of treatment response rates to various anti-viral drugs in Pakistani Hepatitis B Virus infected patients

[Guest guest]

http://7thspace.com/headlines/369742/an_overview_of_treatment_response_rates_to_\

various_anti_viral_drugs_in_pakistani_hepatitis_b_virus_infected_patients.html

An overview of treatment response rates to various anti-viral drugs in Pakistani

Hepatitis B Virus infected patients

Hepatitis B virus (HBV) is one of the leading health problem with up to 350

million affected people worldwide including 4.5 million only in Pakistan. It has

mortality rate of 0.5 to 1.2 million per year worldwide.

Pakistan lies in the endemic region with 3-5% HBV carrier rate in the country.

The present article reviews the literature on the treatment response of HBV

prevalent in Pakistani population.

The average treatment response of Lamivudine and interferon-alpha is 25.81% and

47.95%, respectively. Peg-Interferon was shown to be not effective against the

HBV/HCV (hepatitis C virus)/HDV (hepatitis Delta virus) co-infection.

The present study reveals that interferon-alpha is the most effective therapy

available for HBV infection prevalent in Pakistani population. Genotype C & D are

the most common HBV genotypes in Pakistan and are associated with increased

severity and less response to interferon therapy.

This poses a great challenge for physicians and researchers and further studies

are needed to describe the outcome of the current therapies recommended against

HBV infection in Pakistani population.

Author: Liaqat AliMuhammad IdreesMuhammad AliIrshad-ur RehmanAbrar HussainSamia

AfzalSadia ButtSana SaleemSaira MunirSadaf Badar

Credits/Source: Virology Journal 2011, 8:20

[Guest guest]

http://7thspace.com/headlines/369742/an_overview_of_treatment_response_rates_to_\

various_anti_viral_drugs_in_pakistani_hepatitis_b_virus_infected_patients.html

An overview of treatment response rates to various anti-viral drugs in Pakistani

Hepatitis B Virus infected patients

Hepatitis B virus (HBV) is one of the leading health problem with up to 350

million affected people worldwide including 4.5 million only in Pakistan. It has

mortality rate of 0.5 to 1.2 million per year worldwide.

Pakistan lies in the endemic region with 3-5% HBV carrier rate in the country.

The present article reviews the literature on the treatment response of HBV

prevalent in Pakistani population.

The average treatment response of Lamivudine and interferon-alpha is 25.81% and

47.95%, respectively. Peg-Interferon was shown to be not effective against the

HBV/HCV (hepatitis C virus)/HDV (hepatitis Delta virus) co-infection.

The present study reveals that interferon-alpha is the most effective therapy

available for HBV infection prevalent in Pakistani population. Genotype C & D are

the most common HBV genotypes in Pakistan and are associated with increased

severity and less response to interferon therapy.

This poses a great challenge for physicians and researchers and further studies

are needed to describe the outcome of the current therapies recommended against

HBV infection in Pakistani population.

Author: Liaqat AliMuhammad IdreesMuhammad AliIrshad-ur RehmanAbrar HussainSamia

AfzalSadia ButtSana SaleemSaira MunirSadaf Badar

Credits/Source: Virology Journal 2011, 8:20

[Guest guest]

http://7thspace.com/headlines/369742/an_overview_of_treatment_response_rates_to_\

various_anti_viral_drugs_in_pakistani_hepatitis_b_virus_infected_patients.html

An overview of treatment response rates to various anti-viral drugs in Pakistani

Hepatitis B Virus infected patients

Hepatitis B virus (HBV) is one of the leading health problem with up to 350

million affected people worldwide including 4.5 million only in Pakistan. It has

mortality rate of 0.5 to 1.2 million per year worldwide.

Pakistan lies in the endemic region with 3-5% HBV carrier rate in the country.

The present article reviews the literature on the treatment response of HBV

prevalent in Pakistani population.

The average treatment response of Lamivudine and interferon-alpha is 25.81% and

47.95%, respectively. Peg-Interferon was shown to be not effective against the

HBV/HCV (hepatitis C virus)/HDV (hepatitis Delta virus) co-infection.

The present study reveals that interferon-alpha is the most effective therapy

available for HBV infection prevalent in Pakistani population. Genotype C & D are

the most common HBV genotypes in Pakistan and are associated with increased

severity and less response to interferon therapy.

This poses a great challenge for physicians and researchers and further studies

are needed to describe the outcome of the current therapies recommended against

HBV infection in Pakistani population.

Author: Liaqat AliMuhammad IdreesMuhammad AliIrshad-ur RehmanAbrar HussainSamia

AfzalSadia ButtSana SaleemSaira MunirSadaf Badar

Credits/Source: Virology Journal 2011, 8:20

[Guest guest]

http://7thspace.com/headlines/369742/an_overview_of_treatment_response_rates_to_\

various_anti_viral_drugs_in_pakistani_hepatitis_b_virus_infected_patients.html

An overview of treatment response rates to various anti-viral drugs in Pakistani

Hepatitis B Virus infected patients

Hepatitis B virus (HBV) is one of the leading health problem with up to 350

million affected people worldwide including 4.5 million only in Pakistan. It has

mortality rate of 0.5 to 1.2 million per year worldwide.

Pakistan lies in the endemic region with 3-5% HBV carrier rate in the country.

The present article reviews the literature on the treatment response of HBV

prevalent in Pakistani population.

The average treatment response of Lamivudine and interferon-alpha is 25.81% and

47.95%, respectively. Peg-Interferon was shown to be not effective against the

HBV/HCV (hepatitis C virus)/HDV (hepatitis Delta virus) co-infection.

The present study reveals that interferon-alpha is the most effective therapy

available for HBV infection prevalent in Pakistani population. Genotype C & D are

the most common HBV genotypes in Pakistan and are associated with increased

severity and less response to interferon therapy.

This poses a great challenge for physicians and researchers and further studies

are needed to describe the outcome of the current therapies recommended against

HBV infection in Pakistani population.

Author: Liaqat AliMuhammad IdreesMuhammad AliIrshad-ur RehmanAbrar HussainSamia

AfzalSadia ButtSana SaleemSaira MunirSadaf Badar

Credits/Source: Virology Journal 2011, 8:20